Calvert Holdings, Inc. announced that Michael A. Recny, Ph.D., has been appointed Chief Executive Officer and has been elected a Director of the Company.
He replaces Russ McLauchlan, who will become Executive Chairman and who will also now head the newly formed Executive Committee of Calvert Holdings, w ...
Calvert Research, LLC announced that the U.S. Food and Drug Administration recently accepted the Investigational New Drug application for the Phase I/II trial of ONC201, the lead experimental drug compound being developed by Oncoceutics, Inc., a Calvert Research portfolio company.
Calvert Research, LLC, a business unit of Calvert Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) recently accepted the Inv ...
Calvert Research, LLC, a business unit of Calvert Holdings, Inc., and Oncoceutics, Inc. announced the execution of an Investment Partnership Agreement to support completion of preclinical studies for ONC201, Oncoceutics' experimental anti-cancer compound.
CARY, NC and HUMMELSTOWN, PA - Under the terms of the Agreement, Calvert Research will utilize the extensive resources of its CRO affiliate, Calvert L ...
Satisfied Users & 
Approved Press Releases
